Hyperfine Inc
NASDAQ:HYPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hyperfine Inc
NASDAQ:HYPR
|
US |
Hyperfine Inc
Hyperfine, Inc. is a medical device development company, which engages in providing imaging and monitoring through magnetic resonance imaging to revolutionize healthcare for people. The company is headquartered in Guilford, Connecticut and currently employs 136 full-time employees. The company went IPO on 2021-01-27. The firm provides a Swoop system, which is a portable magnetic resonance imaging (MRI) system capable of providing neuroimaging at the point of care. Its Swoop Portable Magnetic Resonance Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional MRI scanners. MRI is a medical imaging technique used in radiology to image the human body’s anatomy and physiological processes. MRI is used in various clinical settings for medical diagnosis, the staging of disease, and follow-up treatment. The company designed its Swoop system to address an unmet need in point-of-care medical imaging through a combination of hardware and Artificial intelligence (AI)-powered software services. Its hardware uses modern computational power and deep learning advances. Its software addresses the traditional ease-of-use and integration challenges often presented by specialized medical technologies.
Hyperfine, Inc. is a medical device development company, which engages in providing imaging and monitoring through magnetic resonance imaging to revolutionize healthcare for people. The company is headquartered in Guilford, Connecticut and currently employs 136 full-time employees. The company went IPO on 2021-01-27. The firm provides a Swoop system, which is a portable magnetic resonance imaging (MRI) system capable of providing neuroimaging at the point of care. Its Swoop Portable Magnetic Resonance Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional MRI scanners. MRI is a medical imaging technique used in radiology to image the human body’s anatomy and physiological processes. MRI is used in various clinical settings for medical diagnosis, the staging of disease, and follow-up treatment. The company designed its Swoop system to address an unmet need in point-of-care medical imaging through a combination of hardware and Artificial intelligence (AI)-powered software services. Its hardware uses modern computational power and deep learning advances. Its software addresses the traditional ease-of-use and integration challenges often presented by specialized medical technologies.
Revenue: Q4 revenue was $5.3 million, up 128% YoY, driven by 16 unit net sales and broad demand across hospitals, neurology offices and international markets.
Product momentum: Next-generation Swoop with Optive AI is driving adoption—company sold over a dozen next-gen systems since June and sees strong clinical endorsements and deal interest from IDNs.
Margins & cost control: Q4 gross margin was 50.9% (1,530 bps improvement YoY); full-year gross margin was 49.8% (410 bps improvement YoY). R&D and operating expenses declined as the company scaled.
Profitability path: Q4 net loss narrowed to $5.9 million ($0.06/share) from $10.4 million ($0.14/share) a year ago; full-year net loss improved to $35.6 million ($0.43/share).
Balance sheet & runway: Cash and cash equivalents were $35.1 million at year-end (includes $18.4M equity proceeds); an initial $15 million tranche of a up-to-$40M debt facility was raised in March, extending runway into 2028.
2026 guidance: Revenue guide of $20M–$22M (midpoint +55% YoY), gross margin guidance 50%–55%, and total cash burn guidance $26M–$28M (includes debt servicing).
Commercial dynamics: Larger multiunit/IDN deals are in the pipeline but can create quarterly lumpiness due to budget cycles; office neurology market and India approval are new growth vectors.
